Spectrum of genomic alterations in FGFR 3 : current appraisal of the potential role of FGFR 3 in advanced urothelial carcinoma
- 7 July 2016
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 118 (5) , 681-691
Abstract
Molecular analysis has identified subsets of urothelial carcinoma ( UC ) expressing distinct genetic signatures. Genomic alterations in the oncogenic fibroblast growth factor receptor 3 ( FGFR 3 ) pathway are among the most well described in UC and have led to extensive and ongoing investigation of FGFR 3‐targeted therapies in this disease, although no new drugs have yet been approved. Given the unmet need for effective treatments in advanced and metastatic UC , a better understanding of the known molecular alterations of FGFR 3 and of the previous and ongoing clinical investigations of this promising target in UC deserves attention. The objective of the present review is to describe the landscape of alterations and biology of FGFR 3 in UC , comprehensively summarize the current state of UC clinical trials of FGFR 3 inhibitors, and discuss future therapeutic applications. Using the Pubmed and Clinicaltrials.gov databases, articles describing the spectrum and biological activity of FGFR 3 genomic alterations and trials of FGFR 3 inhibitors in UC were identified. Search terms included ‘ FGFR 3 genomic alterations’ and ‘urothelial cancer’ or ‘bladder cancer’. Genomic alterations, including translocations and activating mutations, are increasingly described in advanced and metastatic UC . The majority of clinical trials have been performed in unselected populations; however, recent studies have reported encouraging preliminary data. We argue that routine use of molecular genomic tumour analysis in UC may inform selection of patients for appropriate trials and we further investigate the potential of FGFR 3 as a meaningful clinical target for this difficult disease.Keywords
Funding Information
- Growth, Development, and Disabilities Training Program (T32 HD07009)
This publication has 65 references indexed in Scilit:
- Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutationsCytokine & Growth Factor Reviews, 2015
- FGFR3 Unliganded Dimer Stabilization by the Juxtamembrane DomainJournal of Molecular Biology, 2015
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR InhibitorCancer Discovery, 2012
- The A391E mutation enhances FGFR3 activation in the absence of ligandBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivoBritish Journal of Cancer, 2010
- Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific mannerOncogene, 2009
- Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic TransformationMolecular and Cellular Biology, 2009
- Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancerOncogene, 2007
- Alternative Splicing of Fibroblast Growth Factor Receptor 3 Produces a Secreted Isoform That Inhibits Fibroblast Growth Factor–Induced Proliferation and Is Repressed in Urothelial Carcinoma Cell LinesCancer Research, 2005
- Activation of FGF receptors by mutations in the transmembrane domainOncogene, 1997